Duraibabu Prathyusha sold SGMO

May 24, 2024 · Form 4 insider transaction

Duraibabu Prathyusha sold 1,787 shares of Sangamo Therapeutics, Inc. at $0.60 per share, a transaction worth $1.1K. The trade was recorded as shares withheld for taxes and disclosed on an SEC Form 4, filed 5 days after the transaction.

Direction
Disposed (sell-side)
Shares
1,787
Price
$0.60
Total value
$1.1K
RoleOfficer
SecurityCommon Stock
Transaction codeF: Shares withheld for taxes
Transaction dateMay 24, 2024
Filing dateMay 29, 2024
Shares owned after832,791
OwnershipDirect
10b5-1 planNo
AmendedNo

Footnotes

Represents shares underlying the portions of RSU grants that vested on May 24, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 24, 2024 of $0.60/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.; Includes: (a) 3,222 shares resulting from the May 24, 2024 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 35,069 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 15,375 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, (c) 2,500 shares subject to Reporting Person's June 11, 2021 RSU grant that will vest in one final installment on June 11, 2024 and (d) 712,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter.; The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

View the original Form 4 on SEC EDGAR